Monday, Axsome Therapeutics Inc (NASDAQ:AXSM) released data from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. Narcolepsy is a sleep disorder that makes people very drowsy ...

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant remission of cataplexy compared to placebo ...

Narcolepsy with cataplexy, now known as type 1 narcolepsy, is a chronic neurological disorder that affects a person’s sleep-wake cycle and involves muscle weakness. The condition can cause a person to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has approved a supplemental new drug application ...

Response was defined by an increase in days patients rated their Ability to Concentrate as very good or good (cognitive response), and a ≥50% reduction in cataplexy attacks (cataplexy response).

Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, announced that AXS-12 (reboxetine), a highly selective and potent ...